Roundtable Discussion; The Future of Mineral Sands. Watch the video here.
Or maybe they didn’t renew Lago’s contract as there won’t be any shares soon... they just appointed a new advisor with biotech takeover experience and Astra Zeneca are raising funds this week for unspecified purposes.
Just daydreaming.
So now we also know that Sepsis is a long term after-effect of Covid. Up to 1 in 5 survivors of hospital treatment according to UK Sepsis Trust.
And, yes, unfortunately people die from Sepsis because it causes ARDS.
The first inflection point is likely to be Blautix trial results at some point this quarter. So far all we have been told is that preliminary analysis has shown the effect is 'not trivial'....
Hi Zen - yes, I'm in FARN too as you know.
Hoping for similar here - Merck partnership is gold dust.
I agree, this was a conservative approach - it's one way to keep myself grounded.
Coincidentally I was talking to my son this week about the potential of Clevegen and we came up with a number. Our comparator was Keytruda and the cancers it treats vs the Clevegen cohorts...
You can imagine where we got to...
Back in 2018, before the corticosteroid issue (now resolved), FARN had a mcap of c. £240m. That valuation was on the basis of Traumakine alone as Clevegen wasn't in the mix back then.
At the start of this year, the mcap was nearer £100m and that was mainly due to Clevegen as Traumakine had basically been discounted.
The current mcap is around £210m so we are arguably c. £130m undervalued on that basis.
And that is before the additional Covid demand for Traumakine and the major progress on Clevegen this year.
(Admittedly Traumakine is not at the end if a formal Phase 3 trial, but given the current situation, a positive result from Solidarity or REMAP-CAP would surely shoot it ahead so I've assumed equivalence.)
Not sure if the exact date, but it was earlier this year, before lockdown.
What has always intrigued me is the final bullet point on the first slide '2018 onwards - Ground breaking discovery of the functionality of lymph node lymphatics leading to several targets to prevent cancer metastasis'.
He doesn't mention it in the presentation and I can't see it in any other material. Is this the 'secret weapon'?
Clearly, just as a vaccine will reduce demand for all treatment, nebulisers would reduce demand for ICU treatment. But that doesn't mean there isn't a market for all of them in treating Covid.
Even if the nebuliser prevents 80% of patients from needing ICU (and i doubt it will be this high) that still leaves 20% that would. So IV treatment would only need to be five times more expensive for the two to be compatible in terms in revenues from Covid admissions.... there is a place for both.
Traumakine is already in two if the biggest and high profile Covid trials (Solidarity and REMAP-CAP)
Also, HIBISCUS is an investigator initiated trial - in Harvard Medical School. They would hardly do that if they weren't going to treat patients.
Yes, this is the key to the IV vs Subcutaneous injection question.
It's was written by the Faron team (family to be more accurate!), in order to make a specific point that IV (Traumakine) is far more effective in ICU due to the very different pharmacological effects.
In addition to all the Traumakine news, I'm expecting a significant Clevegen update this quarter too. They will already have data coming in from the expanded CRC cohort (it's been dosed for over three months now), so it won't be too long IMO.
Good news on both fronts could really make things interesting. Not that I'm complaining, I'm thoroughly enjoying the ride!
Volumes were very small in the drift to 290 - there were often days where 20 posts here would exceed the number of trades. So I agree - LTH faith is strong.
We’re attracting a bit more interest now. It’s just so funny that that it’s coming from Traumakine. Don’t get me wrong, Traumakine is likely to make us all a fair bit richer but I invested because of Clevegen and its potential still dwarfs Traumakine. Timing is excellent too, taking attention away from the big play whilst they gather the data from the expanded cohorts and line up the mega-deal. IMO of course.
So Merck have done a deal with the EU, with others likely to follow. Merck have released this news.
FARN need to clarify how their patents protect IV administration and lyophilisation, and what agreements they have with WHO/REMAP-CAP and Merck/other IFN-B1a manufacturers as a result. Surely we have a right to know more about the commercial opportunity and what they are doing about it?
Good spot zumzum. Looks like they have bought Rebif.
https://uk.reuters.com/article/uk-health-coronavirus-eu-treatments-excl/exclusive-eu-secures-potential-covid-19-drugs-from-roche-germanys-merck-source-idUKKBN2491EB
Clearly someone (or someones) believes enough to place that kind of bet. And it looks like they timed it better than me!
Oncology results looking good, Merck deal looking increasingly like a master stroke and Board buying further in big time. Trek Is right on risk/reward here IMO.
My worry with Solidarity is that it's a very blunt tool (very few measures), so it may be difficult to determine optimal timing in disease progression and difference between SC and IV administration.
I'm really hoping that they are sharing data with REMAP-CAP where they should be getting much more specific data, especially as IFN-B1A has its own arm.
The WHO press briefing last week alluded to more sharing between trials. A joint conclusion / announcement would be best of both worlds!
Been building here recently on the way down. Just reached my limit so here I am.
What they're doing with Merck is really interesting (they don't give access to Keytruda lightly!), asthma looks promising and I'm intrigued to see how 'non-trivial' Blautix is!
Hoping the corner is turned now and I've timed it right re fund raises. I'm following the Directors from now on in.
Couldn't agree more. Back where we were a month ago is a good place to be in the absence of news.
And FARN recent history would suggest we'll get an update soon. We're not in control of T news at the moment but Clevegen is another matter. The first expanded CRC cohort has been dosed for over three months now, albeit on a reduced dose. Can't be too long now as it's open label -they know what's going on by now, surely?